AU2004285562B2 - Pigment epithelium-derived factor, novel biological activity and methods of use - Google Patents

Pigment epithelium-derived factor, novel biological activity and methods of use Download PDF

Info

Publication number
AU2004285562B2
AU2004285562B2 AU2004285562A AU2004285562A AU2004285562B2 AU 2004285562 B2 AU2004285562 B2 AU 2004285562B2 AU 2004285562 A AU2004285562 A AU 2004285562A AU 2004285562 A AU2004285562 A AU 2004285562A AU 2004285562 B2 AU2004285562 B2 AU 2004285562B2
Authority
AU
Australia
Prior art keywords
pedf
peptide
vegf
amino acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004285562A
Other languages
English (en)
Other versions
AU2004285562A1 (en
Inventor
Hua Liu
Patrick Tong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2004285562A1 publication Critical patent/AU2004285562A1/en
Application granted granted Critical
Publication of AU2004285562B2 publication Critical patent/AU2004285562B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
AU2004285562A 2003-10-29 2004-10-29 Pigment epithelium-derived factor, novel biological activity and methods of use Ceased AU2004285562B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51537403P 2003-10-29 2003-10-29
US60/515,374 2003-10-29
PCT/US2004/036245 WO2005041887A2 (en) 2003-10-29 2004-10-29 Pigment epithelium-derived factor, novel biological activity and methods of use

Publications (2)

Publication Number Publication Date
AU2004285562A1 AU2004285562A1 (en) 2005-05-12
AU2004285562B2 true AU2004285562B2 (en) 2011-06-09

Family

ID=34549400

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004285562A Ceased AU2004285562B2 (en) 2003-10-29 2004-10-29 Pigment epithelium-derived factor, novel biological activity and methods of use

Country Status (6)

Country Link
US (1) US20080293626A1 (OSRAM)
EP (1) EP1684692A2 (OSRAM)
JP (1) JP2007509984A (OSRAM)
CN (1) CN101014358A (OSRAM)
AU (1) AU2004285562B2 (OSRAM)
WO (1) WO2005041887A2 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054278A2 (en) 2004-11-16 2006-05-26 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Variants of pigment epithelium derived factor and uses thereof
US8841259B2 (en) 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
CA2629519A1 (en) 2005-11-14 2007-05-18 Yeda Research & Development Co. Ltd. At The Weizmann Institute Of Scienc E Improved variants of pigment epithelium derived factor and uses thereof
WO2007095350A2 (en) * 2006-02-15 2007-08-23 Yale University Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments
ES2329636B2 (es) * 2006-02-17 2010-07-26 Universitat De Valencia, Estudi General (Participa Con El 70%) Uso del factor pedf para inducir la auto-renovacion de celulas madre.
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
JPWO2009116529A1 (ja) 2008-03-18 2011-07-21 国立大学法人北海道大学 ポリペプチドおよび当該ポリペプチドを含む医薬組成物
CA2776748A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
EP2508196B1 (en) * 2011-03-23 2018-09-26 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing
US20130046283A1 (en) * 2011-05-05 2013-02-21 Medtronic Vascular, Inc. Methods and intravascular treatment devices for treatment of atherosclerosis
TWI554521B (zh) * 2011-10-19 2016-10-21 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 色素上皮衍生因子衍生之多胜肽於治療禿髮和／或毛髮脫色之用途
CN102757497B (zh) * 2012-07-16 2014-09-17 中山大学 一种抗pedf单克隆抗体及其制备方法和应用
US9938328B2 (en) 2012-09-17 2018-04-10 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating alopecia and/or hair depigmentation
JP6484174B2 (ja) * 2012-09-19 2019-03-20 マクカイ メモリアル ホスピタル 皮膚老化を予防及び／又は改善するためのｐｅｄｆ−由来ポリペプチドの使用
TWI449532B (zh) * 2012-09-19 2014-08-21 Mackay Memorial Hospital 色素上皮衍生因子衍生之多胜肽於預防和／或緩和皮膚老化之用途
US9777048B2 (en) 2012-09-20 2017-10-03 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating osteoarthritis
TWI491407B (zh) * 2012-09-20 2015-07-11 Mackay Memorial Hospital 色素上皮衍生因子衍生之多胜肽於治療骨性關節炎之用途
US9611314B2 (en) 2013-09-13 2017-04-04 The Penn State Research Foundation Functional peptide analogs of PEDF
JP6894236B2 (ja) * 2014-03-26 2021-06-30 デノボ バイオファーマ エルエルシー 免疫刺激活性を有するレトロウイルスベクター
JP6896641B2 (ja) * 2015-03-02 2021-06-30 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 血管新生阻害ペプチド
EA037698B1 (ru) * 2016-10-07 2021-05-12 Брим Байотекнолоджи, Инк. Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
JP6469767B2 (ja) * 2017-07-05 2019-02-13 マクカイ メモリアル ホスピタル 皮膚老化を予防及び／又は改善するためのｐｅｄｆ−由来ポリペプチドの使用
JP6522063B2 (ja) * 2017-08-10 2019-05-29 マクカイ メモリアル ホスピタル 脱毛症及び／又は毛髪色素脱失を治療するためのｐｅｄｆ由来のポリペプチドの使用
AU2019253456A1 (en) * 2018-04-08 2020-11-26 Brim Biotechnology, Inc. Application of PEDF-derived short peptides in the treatment of osteoarthritis
CN111760019B (zh) * 2019-08-16 2023-09-05 董红燕 Pedf在制备保护慢性肺损伤药物中的应用
CN112390877B (zh) * 2019-08-16 2022-10-04 董红燕 Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用
EP4021917A4 (en) * 2019-08-27 2023-05-24 Yeou-Ping Tsao SHORT SYNTHETIC PEPTIDES AND THEIR USES FOR TREATING DEGENERATIVE RETINA DISEASES AND/OR TISSUE DAMAGE
JP7847082B2 (ja) * 2019-10-06 2026-04-16 ブリム バイオテクノロジー インク Ｐｅｄｆ由来短ペプチド（ｐｄｓｐ）を含む組成物及びその使用
CN114057831B (zh) * 2020-08-07 2024-03-12 三凡生技研发股份有限公司 促进血管增生的短链胜肽及其促进糖尿病伤口愈合的用途
WO2025117767A1 (en) * 2023-11-29 2025-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pigment epithelium-derived factor peptides and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010021382A1 (en) * 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US7105496B2 (en) * 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
DE60136444D1 (de) * 2000-02-23 2008-12-18 Univ Northwestern Pharmazeutische zusammensetzung zur angiogenese-hemmung mittels eines pedf-fragmentes
AU2001249835A1 (en) * 2000-04-03 2001-10-15 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
IL147444A0 (en) * 2002-01-03 2002-08-14 Yeda Res & Dev Process for the production of pigment epithelium derived factor (pedf) from human blood and uses thereof
US20030158112A1 (en) * 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US20060189519A1 (en) * 2002-09-26 2006-08-24 Karl Volz Anti-angiogenic fragments fo pigment epithelium-derived factor (pedf)
AU2003297607A1 (en) * 2002-12-02 2004-06-23 Genvec, Inc Materials and methods for treating ocular-related disorders
WO2005089811A1 (en) * 2004-03-12 2005-09-29 Genvec, Inc. Materials for treating vascular leakage in the eye

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STELLMACH V et al., PNAS, 2001, vol.98, no. 5, pages 2593-2597 *

Also Published As

Publication number Publication date
WO2005041887A3 (en) 2005-11-24
US20080293626A1 (en) 2008-11-27
JP2007509984A (ja) 2007-04-19
EP1684692A2 (en) 2006-08-02
CN101014358A (zh) 2007-08-08
WO2005041887A2 (en) 2005-05-12
AU2004285562A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
US20080293626A1 (en) Pigment epithelium-derived factor as a therapeutic agent for vascular leakage
Duh et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth
AU741886B2 (en) Methods and compositions for inhibiting angiogenesis
US20090047335A1 (en) Anti-angiogenic peptides and methods of use thereof
US20090069241A1 (en) Compositions and Methods for Use of Pigment Epithelial Derived Factor (PEDF) Peptide Fragments
JP2002530431A (ja) ＴＧＦβ１−インヒビターペプチド
US6919309B2 (en) Methods and compositions for inhibiting angiogenesis
US8530416B2 (en) Variants of pigment epithelium derived factor and uses thereof
KR20010040906A (ko) 각질세포 성장 인자-2의 치료학적 용도
EP1357930B1 (en) Histidine-rich glycoprotein (hrgp) for inhibiting angiogenesis
US20160367691A1 (en) Targeted enzyme compounds and uses thereof
EP1265627B1 (en) Pharmaceutical compositions for inhibiting angiogenesis by pedf fragments
CN110446501A (zh) 组织激肽释放酶1的剂型
US20030064917A1 (en) Methods and compositions for inhibiting angiogenesis
US7105496B2 (en) Methods and compositions for inhibiting angiogenesis
WO2003004600A2 (en) Improvement of viral uptake into cells and tissues
JP2009505944A (ja) 神経再生ペプチド及びそれらの使用方法
HK1051327B (en) Pharmaceutical compositions for inhibiting angiogenesis by pedf fragments
CA2410699C (en) Methods and compositions for inhibiting angiogenesis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired